RTI Biologics and STAAR Surgical End the Week Near 52-Week Highs

The markets ended the week closing lower two days in a row. Yet small cap biotech companies RTI Biologics

and STAAR Surgical

rose to new 52-week highs of $3.75 and $7.08 per share, respectively, in Friday's trading session.

has been in a very strong uptrend since February and has hit 52-week highs ten times in the past month. It recently posted strong second-quarter results and raised its outlook for the full year. The Florida-based company produces orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. It has a market cap of $201.3 million. The long-term earnings per share growth forecast is 26.9%. The forward P/E ratio forecast is in line with the industry average and the PEG ratio is 0.9. Cash on hand has increased in recent quarters while long-term debt has decreased. Shares are trading more than 37% higher than at the beginning of the year. The stock has outperformed competitors Integra LifeSciences

and Medtronic

, as well as the broader markets, year to date.

recently reported better-than-expected second-quarter results and boosted its guidance. The share price has risen more than 35% since then. The first quarter was the first profitable one since 2000. The California-based company develops, manufactures and sells implantable lenses for the cataracts and refractive surgery, as well as sells related instruments, devices and equipment. Its market cap is $247.9 million. Cash on hand has increased in the past few quarters while long-term debt has decreased. Cash flow from operations has increased in that time as well. Revenue is forecast to be up 15% this year and up 13% in the following year. Shares are trading almost 46% higher than a year ago. The stock has outperformed competitor Cooper Companies

, as well as the broader markets, over the past six months.

Traders interested in biotech exchange traded funds might want to consider the following trades:

Or traders looking for a hedge might want to consider these alternative positions: